A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System
← catalyst calendarNCT06564636 · readout ≤ 499 d
Sponsored by Smith & Nephew, Inc. (industry) · SNN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
119actual
Sites
10
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-26 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2036 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Total Hip Arthroplasty (THA)
- Osteoarthritis
- Degenerative Joint Disease
- Inflammatory Arthritis
- Avascular Necrosis
- Post-traumatic Arthritis
- Congenital Hip Dysplasia
Intervention
- Device: CATALYSTEM
Primary outcome
what the primary-completion date above is the date OFCollared CATALYSTEM™ femoral stem implant survivorship 2 years post-operatively
measured 2 years post-operative
Permalink · SNN's whole pipeline · Catalyst calendar · Every registered study · What changed